| Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance HS Khalil, V Mitev, T Vlaykova, L Cavicchi, N Zhelev Journal of biotechnology 202, 40-49, 2015 | 72 | 2015 |
| Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells HS Khalil, A Goltsov, SP Langdon, DJ Harrison, J Bown, Y Deeni Journal of biotechnology 202, 12-30, 2015 | 43 | 2015 |
| Targeting ATM pathway for therapeutic intervention in cancer HS Khalil, H Tummala, S Chakarov, N Zhelev, DP Lane Biodiscovery 1, e8920, 2012 | 43 | 2012 |
| A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells HS Khalil, SP Langdon, A Goltsov, T Soininen, DJ Harrison, J Bown, ... Oncotarget 7 (46), 75874, 2016 | 37 | 2016 |
| Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono-and combination anti-cancer therapy A Goltsov, Y Deeni, HS Khalil, T Soininen, S Kyriakidis, H Hu, ... Cells 3 (2), 563-591, 2014 | 34 | 2014 |
| Pharmacological inhibition of ATM by KU55933 stimulates ATM transcription HS Khalil, H Tummala, TR Hupp, N Zhelev Experimental Biology and Medicine 237 (6), 622-634, 2012 | 33 | 2012 |
| ATM in focus: A damage sensor and cancer target HS Khalil, H Tummala, N Zhelev Biodiscovery 5, e8936, 2012 | 31 | 2012 |
| NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib IH Kankia, HS Khalil, SP Langdon, PR Moult, JL Bown, YY Deeni Oxidative Medicine and Cellular Longevity 2017, 2017 | 26 | 2017 |
| NRF2 regulates HER2 and HER3 signaling pathway to modulate sensitivity to targeted immunotherapies HS Khalil, SP Langdon, IH Kankia, J Bown, YY Deeni Oxidative Medicine and Cellular Longevity 2016, 2016 | 22 | 2016 |
| NRF2 inhibition causes repression of ATM and ATR expression leading to aberrant DNA Damage Response HS Khalil, Y Deeni BioDiscovery 15, e8964, 2015 | 21 | 2015 |
| Differential genetic advantages in youth and in aging, or how to die healthy HS Khalil, R Petkova, N Zhelev Biotechnology & Biotechnological Equipment 26 (1), 2703-2711, 2012 | 11 | 2012 |
| Novel insights of Ataxia Telangiectasia Mutated (ATM) regulation and its potential as a target for therapeutic intervention in cancer HS Khalil, H Tummala, OA Oluwaseun, N Zhelev Current Opinion in Biotechnology, S115-S116, 2011 | 11 | 2011 |
| Cancer research and personalised medicine: a new approach to modelling time-series data using analytical methods and Half systems MA Idowu, A Goltsov, HS Khalil, H Tummala, N Zhelev, J Bown Current Opinion in Biotechnology, S59, 2011 | 10 | 2011 |
| Repair, abort, ignore? Strategies for dealing with UV damage H Tummala, HS Khalil, N Zhelev Biotechnology & Biotechnological Equipment 25 (3), 2443-2446, 2011 | 9 | 2011 |
| A novel quantitative systems biology approach to cancer research and treatment R Clyde, H Tummala, HS Khalil, K Goszcz, I Lucka, MG Tupone, M Zwirek, ... Current Opinion in Biotechnology 22 (S1), S58-S58, 2011 | 7 | 2011 |
| Low oxygen affinity in reptilian hemoglobin D: prediction of residue interactions in Geochelone carbonaria HbD by homology modeling G Lutfullah, HS Khalil, F Amin, N Azhar The Protein Journal 27, 141-150, 2008 | 7 | 2008 |
| Reverse engineering of drug induced DNA damage response signalling pathway reveals dual outcomes of ATM kinase inhibition MA Idowu, HS Khalil, JL Bown, N Zhelev Biodiscovery 9, e8954, 2013 | 6 | 2013 |
| Quantitative analysis of proliferation behaviour of ovarian cancer cells with the dynamics of reactive oxygen species production and sequestration Y Deeni, H Khalil, A Goltsov, S Langdon, D Harrison, J Bown Journal of Biotechnology, S12, 2014 | 4 | 2014 |
| Pharmacological inhibition of ATM results in mitochondrial biogenesis in AMPK independent manner. HS Khalil, H Tummala, L DeCaris, N Zhelev Cancer Research 73 (8_Supplement), 1697-1697, 2013 | 4 | 2013 |
| Advocating the need of a systems biology approach for personalised prognosis and treatment of B-CLL patients H Tummala, A Goltsov, HS Khalil, A Sproul, F Scott, V Mitev, N Zhelev Biodiscovery 6 (4), 2012 | 4 | 2012 |
Nikolai ZhelevProfessor of Medical Biotechnology, University of Abertay DundeeVerified email at abertay.ac.uk
